Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen GAAP Operating Income: $9,080M in FY2025, up 25.1% from a year earlier.
Latest, FY2025
9,080
Period ended Dec 31, 2025
Change on a year earlier
+25.1%
7,258 in FY2024
History
7 years
Since FY2019
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| GAAP operating income | $ | 2,720 | $ | 2,311 | $ | 9,080 | $ | 7,258”
Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Reported in Form 8-K Reconciliations of GAAP to Non-GAAP Measures.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | GAAP Operating Income ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9,080 | +25.1% | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 7,258 | -8.1% | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 7,897 | -17.4% | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 9,566 | +25.2% | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 7,639 | -16.4% | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 9,139 | -5.5% | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 9,674 | – | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
Cite this data
StockData. (2026). Amgen GAAP Operating Income ($M), annual FY2019–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gaap-op-inc-8k
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.